For Research Use Only

TDP-43 Polyclonal antibody Catalog Number: 10782-2-AP Featured Product 15


Featured Product 1591 Publications




Basic Information	Catalog Number: 10782-2-AP	GenBank Accession Number: BC001487		Purification Method: Antigen affinity purification	
	Concentration:GeneID (NCBI):600 ug/ml23435Source:UNIPROT ID:			Recommended Dilutions: WB: 1:2000-1:10000	
				IP: 0.5-4.0 ug for 1.0-3.0 mg of total	
	Rabbit	Q13148		protein lysate IHC: 1:2000-1:8000	
	Isotype: IgG	Full Name: TAR DNA binding protein Calculated MW: 43 kDa Observed MW: 44 kDa		IF-Fro: 1:1000-1:4000 IF/ICC: 1:3000-1:12000 FC (Intra): 0.40 ug per 10 [^] 6 cells in a 100 μl suspension ChIP: 1:10-1:100	
Applications	Tested Applications:			ols:	
	WB, IHC, IF/ICC, IF-Fro, FC (Intra), IP, ChIP, ELISA Cited Applications: WB, IHC, IF, IP, CoIP, ChIP, RIP, ELISA, IEM			WB : SH-SY5Y cells, HeLa cells, C2C12 cells, Neuro-2a cells IP : HeLa cells,	
	Species Specificity: human, mouse, rat, zebrafish		-	IHC : human gliomas tissue, human brain (FTLD-U) tissue, mouse brain tissue	
	Cited Species: human, mouse, rat, monkey, chicken, zebrafish,		IF-Fro : rat bra	IF-Fro : rat brain tissue, mouse brain tissue	
	hamster, yeast, horse, seal		IF/ICC : HeLa	IF/ICC : HeLa cells,	
	Note-IHC: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0		FC (Intra) : He	FC (Intra) : HeLa cells,	
			ChIP : HeLa ce	ChIP : HeLa cells,	
Background Information	TDP-43 has since been shown to translational regulation and pre- gene. In 2006 Neumann et al. fou collectively known as pathologi and alpha-synuclein-negative fm Proteintech's 10782-2-AP antibo intact 43 kDa protein as well as a Various forms of TDP-43 exist, in kDa glycosylated form, 75 kDa h	bind RNA as well as DN mRNA splicing. For ins und that hyperphosphor cal TDP-43, play a major ontotemporal dementia dy is a rabbit polyclona all posttranslationally iccluding 18-35 kDa of cl yperphosphorylated fo DP-43 has been reported	IA, and have multipl tance, it is reported to ylated, ubiquitinate or role in the disease a (FTLD-U) and in an al antibody recognizi modified and trunca leaved C-terminal fr rm, and 90-300 kDa ed to be overexpress	o regulate alternate splicing of the CTFI d and/or cleaved forms of TDP-43, mechanisms of ubiquitin-positive, tau- yotrophic lateral sclerosis (ALS). ng N-terminal TDP-43. It recognizes the ted forms in multiple applications. agments, 45-50 kDa phospho-protein, 55 cross-linked form. (17023659, 19823856 ed in triple negative breast cancer	
	TDP-43 has since been shown to translational regulation and pre- gene. In 2006 Neumann et al. fou collectively known as pathologi, and alpha-synuclein-negative fr Proteintech's 10782-2-AP antibo intact 43 kDa protein as well as a Various forms of TDP-43 exist, in kDa glycosylated form, 75 kDa h 21666678, 22193176) Recently T (TNBC) and it may be a potential	bind RNA as well as DN mRNA splicing. For ins und that hyperphosphor cal TDP-43, play a majo ontotemporal dementi- dy is a rabbit polyclona all posttranslationally i ccluding 18-35 kDa of cl yperphosphorylated fo DP-43 has been reported target for TNBC diagno	IA, and have multipl tance, it is reported to ylated, ubiquitinate or role in the disease a (FTLD-U) and in arr al antibody recognizi modified and trunca leaved C-terminal fr rrm, and 90-300 kDa ed to be overexpress osis and drug design	e functions in transcriptional repression, o regulate alternate splicing of the CTFF d and/or cleaved forms of TDP-43, mechanisms of ubiquitin-positive, tau- yotrophic lateral sclerosis (ALS). ng N-terminal TDP-43. It recognizes the ted forms in multiple applications. agments, 45-50 kDa phospho-protein, 55 cross-linked form. (17023659, 19823856, ed in triple negative breast cancer (29581274)	
	TDP-43 has since been shown to translational regulation and pre- gene. In 2006 Neumann et al. fou collectively known as pathologi and alpha-synuclein-negative fm Proteintech's 10782-2-AP antibo intact 43 kDa protein as well as a Various forms of TDP-43 exist, in kDa glycosylated form, 75 kDa h 21666678, 22193176) Recently T (TNBC) and it may be a potential Author	bind RNA as well as DN mRNA splicing. For ins und that hyperphosphor cal TDP-43, play a major ontotemporal dementia dy is a rabbit polyclona all posttranslationally i ccluding 18-35 kDa of cl yperphosphorylated fo DP-43 has been reported target for TNBC diagno	IA, and have multipl tance, it is reported t ylated, ubiquitinate or role in the disease a (FTLD-U) and in an al antibody recognizi modified and trunca leaved C-terminal fr rm, and 90-300 kDa ed to be overexpress osis and drug design	e functions in transcriptional repression o regulate alternate splicing of the CTF d and/or cleaved forms of TDP-43, mechanisms of ubiquitin-positive, tau- yotrophic lateral sclerosis (ALS). ng N-terminal TDP-43. It recognizes the ted forms in multiple applications. agments, 45-50 kDa phospho-protein, 52 cross-linked form. (17023659, 19823856 ed in triple negative breast cancer (29581274) Application	
	TDP-43 has since been shown to translational regulation and pre- gene. In 2006 Neumann et al. fou collectively known as pathologi and alpha-synuclein-negative fm Proteintech's 10782-2-AP antibo intact 43 kDa protein as well as a Various forms of TDP-43 exist, in kDa glycosylated form, 75 kDa h 21666678, 22193176) Recently T (TNBC) and it may be a potential Author Kasey L Jackson	bind RNA as well as DN mRNA splicing. For ins und that hyperphosphor cal TDP-43, play a majo ontotemporal dementi- dy is a rabbit polyclona all posttranslationally u iccluding 18-35 kDa of cl yperphosphorylated fo DP-43 has been reporte target for TNBC diagno Pubmed ID 26445725	IA, and have multipl tance, it is reported to ylated, ubiquitinate or role in the disease a (FLD-U) and in arr al antibody recognizi modified and trunca leaved C-terminal fr rm, and 90-300 kDa ed to be overexpress osis and drug design Journal Mol Ther Methods Cl	e functions in transcriptional repression o regulate alternate splicing of the CTF d and/or cleaved forms of TDP-43, mechanisms of ubiquitin-positive, tau- yotrophic lateral sclerosis (ALS). ng N-terminal TDP-43. It recognizes the ted forms in multiple applications. agments, 45-50 kDa phospho-protein, 52 cross-linked form. (17023659, 19823856 ed in triple negative breast cancer (29581274) Application in Dev WB	
	TDP-43 has since been shown to translational regulation and pre- gene. In 2006 Neumann et al. fou collectively known as pathologi and alpha-synuclein-negative fr Proteintech's 10782-2-AP antibo intact 43 kDa protein as well as a Various forms of TDP-43 exist, in kDa glycosylated form, 75 kDa h 21666678, 22193176) Recently T (TNBC) and it may be a potential Author Kasey L Jackson Jinwal Umesh K UK	bind RNA as well as DN mRNA splicing. For ins und that hyperphosphor cal TDP-43, play a major ontotemporal dementia dy is a rabbit polyclona all posttranslationally in cluding 18-35 kDa of cl yperphosphorylated fo DP-43 has been reported target for TNBC diagnor Pubmed ID 26445725 19793966	IA, and have multipl tance, it is reported t ylated, ubiquitinate or role in the disease a (FTLD-U) and in an al antibody recognizi modified and trunca leaved C-terminal fr rm, and 90-300 kDa ed to be overexpress osis and drug design Journal Mol Ther Methods CI J Neurosci	e functions in transcriptional repression o regulate alternate splicing of the CTF d and/or cleaved forms of TDP-43, mechanisms of ubiquitin-positive, tau- yotrophic lateral sclerosis (ALS). ng N-terminal TDP-43. It recognizes the ted forms in multiple applications. agments, 45-50 kDa phospho-protein, 52 cross-linked form. (17023659, 19823856 ed in triple negative breast cancer (29581274) Application	
	TDP-43 has since been shown to translational regulation and pre- gene. In 2006 Neumann et al. fou collectively known as pathologi and alpha-synuclein-negative fm Proteintech's 10782-2-AP antibo intact 43 kDa protein as well as a Various forms of TDP-43 exist, in kDa glycosylated form, 75 kDa h 21666678, 22193176) Recently T (TNBC) and it may be a potential Author Kasey L Jackson	bind RNA as well as DN mRNA splicing. For ins und that hyperphosphor cal TDP-43, play a major ontotemporal dementia dy is a rabbit polyclona all posttranslationally in cluding 18-35 kDa of cl yperphosphorylated fo DP-43 has been reported target for TNBC diagnor Pubmed ID 26445725 19793966	IA, and have multipl tance, it is reported to ylated, ubiquitinate or role in the disease a (FLD-U) and in arr al antibody recognizi modified and trunca leaved C-terminal fr rm, and 90-300 kDa ed to be overexpress osis and drug design Journal Mol Ther Methods Cl	e functions in transcriptional repressior o regulate alternate splicing of the CTF d and/or cleaved forms of TDP-43, mechanisms of ubiquitin-positive, tau- yotrophic lateral sclerosis (ALS). ng N-terminal TDP-43. It recognizes the ted forms in multiple applications. agments, 45-50 kDa phospho-protein, 5 cross-linked form. (17023659, 19823850 ed in triple negative breast cancer (29581274) Application in Dev WB	
Background Information Notable Publications	TDP-43 has since been shown to translational regulation and pre- gene. In 2006 Neumann et al. fou collectively known as pathologi and alpha-synuclein-negative fr Proteintech's 10782-2-AP antibo intact 43 kDa protein as well as a Various forms of TDP-43 exist, in kDa glycosylated form, 75 kDa h 21666678, 22193176) Recently T (TNBC) and it may be a potential Author Kasey L Jackson Jinwal Umesh K UK	bind RNA as well as DN mRNA splicing. For ins und that hyperphosphor cal TDP-43, play a majo ontotemporal dementia dy is a rabbit polyclona all posttranslationally i including 18-35 kDa of cl yperphosphorylated fo DP-43 has been reporte target for TNBC diagno Pubmed ID 26445725 19793966 33003404	IA, and have multipl tance, it is reported t ylated, ubiquitinate or role in the disease a (FTLD-U) and in an al antibody recognizi modified and trunca leaved C-terminal fr rm, and 90-300 kDa ed to be overexpress osis and drug design Journal Mol Ther Methods CI J Neurosci	e functions in transcriptional repression o regulate alternate splicing of the CTF d and/or cleaved forms of TDP-43, mechanisms of ubiquitin-positive, tau- yotrophic lateral sclerosis (ALS). ng N-terminal TDP-43. It recognizes the ted forms in multiple applications. agments, 45-50 kDa phospho-protein, 52 cross-linked form. (17023659, 19823856 ed in triple negative breast cancer (29581274) Application in Dev WB	

This product is exclusively available under Proteintech Group brand and is not available to purchase from any other manufacturer.


Selected Validation Data




Chromatin was prepared from HeLa cells, cells were fixed with formaldehyde for 10 minutes. The ChIP was performed with 15 µg of cross-linked chromatin, 5 µg of TDP-43 Antibody(10782-2-AP) or 5 µg of Normal Rabbit IgG (30000-0-AP), and 30 µl of Protein A Magarose Beads. The immunoprecipitated DNA was quantified by real time PCR. Primers are located in the first kb of the transcribed region.




40X of FTLD-U case stained by 10782-2-AP and 60019-2-1g, showing dystrophic neurites. (Figs were provided by Linda K. Kwong).



Various lysates were subjected to SDS PAGE followed by western blot with 10782-2-AP (TDP-43 antibody) at dilution of 1:5000 incubated at room temperature for 1.5 hours.




Immunohistochemical analysis of paraffinembedded mouse brain tissue slide using 10782-2-AP (TDP-43 (N-terminal) antibody) at dilution of 1:5000 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).





Immunohistochemical analysis of paraffinembedded human gliomas tissue slide using 10782-2-AP (TDP-43 antibody) at dilution of 1:4000 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).




Immunohistochemical analysis of paraffinembedded human gliomas tissue slide using 10782-2-AP (TDP-43 antibody) at dilution of 1:4000 (under 10x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).









Immunohistochemical analysis of paraffinembedded mouse brain tissue slide using 10782-2-AP (TDP-43 antibody) at dilution of 1:2000 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).




WB result of TDP-43 antibody (10782-2-AP; 1:30000; incubated at room temperature for 1.5 hours) with sh-Control and sh-TDP-43 transfected HeLa cells.









Immunohistochemical analysis of paraffinembedded mouse brain tissue slide using 10782-2-AP (TDP-43 antibody) at dilution of 1:2000 (under 10x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0). IP result of anti-TDP-43 (IP:10782-2-AP, 4ug; Detection:10782-2-AP 1:50000) with HeLa cells lysate 1520 ug. Immunofluorescent analysis of (4% PFA) fixed HeLa cells using TDP-43 antibody (10782-2-AP) at dilution of 1:6000 and CoraLite@488-Conjugated AffiniPure Goat Anti-Rabbit IgG(H+L), CL594phalloidin (red).



1X10^6 HeLa cells were intracellularly stained with 0.4 ug Anti-Human TDP-43 (10782-2-AP) and CoraLite®488-Conjugated AffiniPure Goat Anti-Rabbit IgG(H+L) at dilution 1:1000 (red), or 0.4 ug Isotype Control. Cells were fixed and permeabilized with Transcription Factor Staining Buffer Kit (PF00011).



Immunofluorescent analysis of (4% PFA) fixed frozen OCT-embedded rat brain tissue using TDP-43 antibody (10782-2-AP) at dilution of 1:2000 and CoraLite® 488-Conjugated Goat Anti-Rabbit IgG(H+L) (SA00013-2), CoraLite® 594 GFAP antibody (CL594-16825, red).



Immunofluorescent analysis of (4% PFA) fixed frozen OCT-embedded mouse brain tissue using TDP-43 antibody (10782-2-AP) at dilution of 1:2000 and CoraLite®647-conjugated F(ab, MAP2 antibody (67015-1-Ig, Clone: 1C3E6, green), CoraLite®594 GFAP antibody (CL594-16825, red).